Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Uros Smrdel
Intermittent Chemotherapy and Erlotinib for Nonsmokers or Light Smokers With Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial
Journal of Biomedicine and Biotechnology
Related publications
A Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients With Advanced EGFR Wild-Type Non-Small Cell Lung Cancer
BMC Research Notes
Biochemistry
Medicine
Genetics
Molecular Biology
Prolonged Response to First-Line Erlotinib for Advanced Lung Adenocarcinoma
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
Successful Rechallenge With Gefitinib for an Initial Erlotinib-Responder With Advanced Lung Adenocarcinoma
Tuberculosis and Respiratory Diseases
Pulmonary
Infectious Diseases
Respiratory Medicine
Gemcitabine Plus Vinorelbine as First-Line Chemotherapy in Advanced Nonsmall Cell Lung Carcinoma a Phase II Trial
Cancer
Cancer Research
Oncology
Phase II Trial of Sequential Gefitinib After Minor Response or Partial Response to Chemotherapy in Chinese Patients With Advanced Non-Small-Cell Lung Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
A Phase 2 Trial of Erlotinib in Patients With Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus
Cancer
Cancer Research
Oncology
Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Combination of Chemotherapy and Gefitinib as First-Line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: A Randomized Controlled Trial
International Journal of Cancer
Cancer Research
Oncology
Efficacy of Bevacizumab Plus Erlotinib Versus Erlotinib Alone in Advanced Non-Small-Cell Lung Cancer After Failure of Standard First-Line Chemotherapy (BeTa): A Double-Blind, Placebo-Controlled, Phase 3 Trial
The Lancet
Medicine
